Why the CSL share price rose on Thursday
We look at the highlights from the biotech’s interim results, released to the market on Thursday, 18 February.
CSL share price up on interim report
Despite concerns over plasma collection performance, analysts remained bullish on CSL heading into its first-half results, with the stock carrying an Overweight rating, on average, according to the Wall Street Journal.
This comes even as the biotech has struggled in the last six months, with the stock trading flat in that period.
Share price gyrations aside, CSL handed down a strong set of interim results on Thursday, revealing a surge in profits and a stable, but growing, dividend. Investors seized on this report, with the stock opening at the $295 mark. While the stock traded lower following that morning 'pop', it remained up 3.23%, at $290.24 per share by the afternoon session.
On the bottom-line, the biotech giant said that its net profits after tax (NPAT) hit USD$1,810 million, representing a year-over-year increase of 44%, on a constant currency basis. Earnings per share grew in step, also up 44%.
Group sales hit US$5.7 billion in the half, up 15% on a constant currency basis.
Looking at some of the company's operational highlights, CSL's Seqirus business arm reported total revenue growth of 38%, while seasonal influenza vaccine sales rose an impressive 44%.
For income focused investors, CSL continued to raise its dividend, declaring an interim dividend of US$1.04 per share, an increase of 9%.
CSL share price: The outlook
Despite that growth, commenting on the expectation for Seqirus’ performance in the second half of FY21, CSL’s CEO, Paul Perreault said:
‘Seqirus is performing well as strong demand for influenza vaccines together with our differentiated products portfolio will see it deliver another strong profitable year. Consistent with the seasonal nature of the business we anticipate, however, a loss in the second half of the year.’
Commenting more broadly on the impact that the pandemic will continue to have on the company as well as the strategies CSL is implementing to mitigate this impact, Mr Perreault said:
'COVID-19, however, will continue to have an impact on CSL. Our plasma collections have been adversely affected during the pandemic. To combat this, we have implemented a number of initiatives to increase plasma collections and introduced a customer fulfilment process to ensure the equitable distribution of medicines to patients.'
Looking ahead, for the full-year management said they expected CSL to reported total FY21 net profit, after tax, of between US$2,170 million and US$2,265 million – on a constant currency basis.
Wilsons, who remain Overweight on the stock said today's interim results were 'materially ahead of our forecasts and consensus.’ The broker also reiterated its $345 price target on CSL, while saying they expected the biotech’s full-year net profits to come in at US$2,300 million – a figure that represents the top end of CSL’s guidance range.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk. Please see important Research Disclaimer.
Please also note that the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.